What is Vitexnegheteroin E and where does it come from?

Vitexnegheteroin E is a bioactive secondary metabolite isolated from Vitex negundo (nirgundi), a medicinal shrub native to tropical Asia and widely used in Ayurvedic and Traditional Chinese Medicine. It belongs to a chemically diverse class of phenolic or terpenoid compounds found in the plant's leaves, alongside flavonoids like isoorientin, vitexin, and cynaroside, as well as phenolic acids such as chlorogenic acid. The compound's precise chemical structure and concentration in plant tissue have not been fully characterized in widely accessible peer-reviewed literature.

How does Vitexnegheteroin E inhibit nitric oxide production?

Vitexnegheteroin E is reported to inhibit lipopolysaccharide (LPS)-induced nitric oxide (NO) production in cell-based inflammatory models, most likely by interfering with the expression or activity of inducible nitric oxide synthase (iNOS), the enzyme responsible for NO overproduction during immune activation. This inhibitory action may involve suppression of upstream signaling through NF-κB or MAPK pathways triggered by TLR4 receptor engagement with LPS. These mechanistic details are inferred from analogy with structurally related V. negundo phenolics, as compound-specific pathway studies have not been published for Vitexnegheteroin E independently.

Are there any safety concerns or drug interactions associated with Vitexnegheteroin E?

Dedicated safety and toxicology data for Vitexnegheteroin E are absent from the published literature, precluding firm conclusions about its side effect profile. A significant concern with Vitex negundo-derived materials is pesticide contamination—chlorpyrifos was detected at up to 42.98% in callus cultures—making source verification and third-party testing essential for any commercially prepared product. Additionally, molecular docking data for related V. negundo phenolics suggest potential inhibition of CYP2C9, which could alter plasma levels of drugs metabolized by this enzyme, including warfarin and phenytoin, warranting caution in polypharmacy contexts.

What is the recommended dosage of Vitexnegheteroin E or Vitex negundo extract?

No standardized dosage for Vitexnegheteroin E has been established through clinical trials or regulatory review. Traditional Ayurvedic use of Vitex negundo typically involves leaf decoctions prepared from approximately 5–10 grams of dried leaf material per serving, though this does not translate to a specific Vitexnegheteroin E dose. Commercial V. negundo supplements are not currently standardized to Vitexnegheteroin E content, and individuals should consult a qualified healthcare provider before use, particularly given the lack of human pharmacokinetic and safety data.

What is the antioxidant strength of Vitexnegheteroin E compared to other plant compounds?

Vitexnegheteroin E demonstrates antioxidant activity through radical-scavenging capacity in cell-based assays, with related Vitex negundo fractions showing DPPH IC50 values between 45–79 mg/mL. This places it within a moderate range of antioxidant potency; however, direct head-to-head comparisons with standardized compounds like vitamin C or quercetin are limited in the literature. The actual bioavailability and in vivo antioxidant effects in humans remain to be fully characterized.

How does Vitexnegheteroin E reduce oxidative stress at the cellular level?

Vitexnegheteroin E reduces reactive oxygen species (ROS) burden through phenolic radical-scavenging mechanisms demonstrated in cell-based assays. As a component of Vitex negundo's phenolic profile, it neutralizes free radicals that would otherwise damage cellular structures and trigger inflammatory pathways. This ROS-reduction capacity contributes to the plant's traditional use in managing inflammation-related conditions.

Is Vitexnegheteroin E the most potent active compound in Vitex negundo, or are other constituents equally important?

Vitexnegheteroin E is one of several bioactive phenolics in Vitex negundo, but the plant's pharmacological effects likely result from synergistic interactions among multiple constituents rather than from a single dominant compound. Research has identified antioxidant and anti-inflammatory activities across the plant's phenolic fraction, suggesting that whole-plant extracts or standardized fractions may be more therapeutically relevant than isolated Vitexnegheteroin E alone. The relative contribution of Vitexnegheteroin E to overall efficacy has not been systematically quantified in clinical studies.

Vitexnegheteroin E

Vitexnegheteroin E is a phenolic or terpenoid-class secondary metabolite isolated from Vitex negundo that contributes to antioxidant activity through free-radical scavenging and inhibition of lipopolysaccharide (LPS)-induced nitric oxide (NO) production in macrophage models. Preclinical in vitro data position it within a broader family of Vitex negundo bioactives that suppress oxidative and inflammatory signaling, though compound-specific quantitative efficacy data remain limited to early-phase laboratory investigations.

Category: Compound Evidence: 1/10 Tier: Preliminary

Vitexnegheteroin E — Hermetica Encyclopedia

Origin & History

Vitexnegheteroin E is a bioactive phytochemical isolated from Vitex negundo (nirgundi), a deciduous shrub native to tropical and subtropical Asia, including India, China, Sri Lanka, and Southeast Asia. The plant thrives in riverbanks, roadsides, and forest margins at low to mid elevations, tolerating diverse soil types. It has been cultivated and harvested for millennia in Ayurvedic and Traditional Chinese Medicine systems, with leaves, roots, and seeds all yielding medicinally relevant secondary metabolites.

Historical & Cultural Context

Vitex negundo, the parent plant of Vitexnegheteroin E, carries a documented medicinal history spanning over 2,000 years across Ayurvedic, Unani, and Traditional Chinese Medicine systems, where it is recognized under names including nirgundi (Sanskrit), man jing zi (Chinese), and lagundi (Filipino). In Ayurveda, the plant is classified as one of the Dashamoola (ten roots) group and prescribed for pain, inflammation, fevers, and nervous disorders, with mature leaves consumed orally or applied topically as poultices. Traditional Chinese practitioners utilized the fruits and leaves for dispersing wind-cold, relieving headache, and treating rheumatic complaints, reflecting the plant's widespread geographic and cultural reach. The isolation and characterization of specific compounds such as Vitexnegheteroin E represents a modern phytochemical refinement of this long-standing empirical tradition, translating folk observations into molecular pharmacology.

Health Benefits

- **Antioxidant Activity**: Vitexnegheteroin E contributes to the radical-scavenging capacity characteristic of Vitex negundo phenolics, reducing reactive oxygen species (ROS) burden in cell-based assays; related fractions from V. negundo show DPPH IC50 values in the range of 45–79 mg/mL.
- **Inhibition of LPS-Induced Nitric Oxide**: The compound suppresses nitric oxide production stimulated by lipopolysaccharide, a hallmark of innate immune overactivation, suggesting modulation of inducible nitric oxide synthase (iNOS) expression in macrophage-like systems.
- **Anti-Inflammatory Support**: By limiting NO overproduction, Vitexnegheteroin E may help attenuate downstream pro-inflammatory cascades associated with NF-κB and MAPK pathway activation, consistent with the broader anti-inflammatory profile documented for V. negundo extracts.
- **Oxidative Stress Enzyme Modulation**: Structurally related V. negundo phenolics demonstrate molecular docking affinity toward superoxide dismutase and catalase targets (binding scores >100), suggesting Vitexnegheteroin E may similarly modulate endogenous antioxidant enzyme activity.
- **Potential Cytoprotection**: Suppression of LPS-triggered oxidative bursts implies a cytoprotective role for Vitexnegheteroin E in tissues exposed to inflammatory stimuli, a property shared by co-occurring flavonoids such as isoorientin and chlorogenic acid from the same plant.
- **Complementary Phytochemical Synergy**: Within the complex phytochemical matrix of V. negundo, Vitexnegheteroin E likely acts alongside agnuside, negundoside, and vitexin to provide additive or synergistic antioxidant and anti-inflammatory effects documented in whole-extract studies.

How It Works

Vitexnegheteroin E exerts antioxidant effects primarily through direct hydrogen atom transfer or single-electron transfer to neutralize free radicals, a mechanism shared with structurally related phenolic and terpenoid constituents of Vitex negundo. Its inhibition of LPS-induced nitric oxide production points toward downregulation of inducible nitric oxide synthase (iNOS) at the transcriptional or post-translational level, likely mediated by interference with NF-κB nuclear translocation or MAPK signaling cascades activated by toll-like receptor 4 (TLR4) ligation. Molecular docking analyses of chemically analogous V. negundo phenolics reveal strong binding affinities toward xanthine oxidase, superoxide dismutase, and catalase—enzymes central to ROS metabolism—suggesting Vitexnegheteroin E may similarly occupy active-site or allosteric pockets to modulate enzymatic radical generation. The cumulative effect is a reduction in oxidative and nitrosative stress markers, positioning the compound as a dual-action antioxidant and anti-neuroinflammatory agent pending confirmatory mechanistic studies.

Scientific Research

Research on Vitexnegheteroin E as a discrete compound is extremely limited, with no independently published clinical trials, pharmacokinetic studies, or randomized controlled trials identified in the peer-reviewed literature as of the current review. Available evidence derives entirely from in vitro phytochemical profiling, GC-MS and LC-MS/MS characterization of V. negundo extracts, and molecular docking simulations performed on structurally related co-isolated phenolics. Antioxidant data for V. negundo fractions report DPPH IC50 values of 45.3 mg/mL (acetone extract) and 79.4 mg/mL (methanol extract), providing indirect context for the activity class to which Vitexnegheteroin E belongs, but compound-specific IC50 values have not been rigorously published. The evidence base must be characterized as preliminary and largely inferential; direct attribution of biological effects specifically to Vitexnegheteroin E requires isolation, structural confirmation, and dedicated in vitro and in vivo dose-response experiments.

Clinical Summary

No clinical trials investigating Vitexnegheteroin E in human subjects have been reported in the accessible scientific literature. The compound's pharmacological profile is inferred from in vitro macrophage-based NO-inhibition assays and antioxidant screening studies conducted on crude or semi-purified Vitex negundo fractions. Outcome measures such as iNOS suppression and DPPH radical scavenging have been quantified for whole-plant extracts but not attributed with statistical confidence to Vitexnegheteroin E specifically. Confidence in any clinical application is therefore very low, and human efficacy, optimal dosing, and safety cannot be established from existing data alone.

Nutritional Profile

Vitexnegheteroin E is a trace-level secondary metabolite within Vitex negundo tissue and does not contribute meaningfully to macronutrient or micronutrient intake. The broader leaf matrix contains phenolic compounds at approximately 2.70 mg/g dry weight, proteins at 2.49 mg/g, and phytosterols at approximately 1.1 mg/g, with predominant fatty acid constituents including octadecadienoic acid (linoleic acid methyl ester, 21.93% in wild leaves) and hexadecanoic acid methyl ester. Flavonoids isoorientin, vitexin, isovitexin, and cynaroside (luteolin-7-glucoside) are co-present alongside phenolic acids such as chlorogenic acid and benzoic acid; the relative concentration of Vitexnegheteroin E within this matrix has not been quantified. Bioavailability of phenolic and terpenoid compounds from V. negundo is influenced by food-matrix interactions, extraction solvent polarity, and first-pass hepatic metabolism, none of which have been specifically assessed for Vitexnegheteroin E.

Preparation & Dosage

- **Traditional Leaf Decoction**: Dried V. negundo leaves prepared as aqueous decoction (5–10 g leaf material per 200 mL water); Vitexnegheteroin E content in this form is unquantified.
- **Methanolic Extract (Laboratory Standard)**: Soxhlet extraction with methanol used in research settings; no standardized commercial extract specifying Vitexnegheteroin E content is currently available.
- **Acetone Extract**: Used in antioxidant assays; acetone fractions yield DPPH IC50 ~45 mg/mL for total extract activity.
- **Essential Oil (Hydrodistillation)**: Yields terpenoid-rich fractions dominated by epiglobulol (30.31%) and terpinen-4-ol (9.42%); Vitexnegheteroin E presence in essential oil fractions is not confirmed.
- **Standardized Supplement Forms**: No commercial supplement is currently standardized to Vitexnegheteroin E content; general V. negundo supplements are marketed but lack compound-specific standardization.
- **Effective Human Dose**: Not established; no clinical dose-finding studies exist for Vitexnegheteroin E or V. negundo extracts specifying this compound.

Synergy & Pairings

Within the Vitex negundo phytochemical complex, Vitexnegheteroin E likely acts synergistically with co-occurring flavonoids isoorientin and cynaroside, which independently modulate superoxide dismutase and catalase activity, creating a multi-target antioxidant network that addresses both enzymatic and non-enzymatic ROS generation simultaneously. Pairing V. negundo extracts with vitamin C or quercetin-rich botanicals is theoretically supportive, as ascorbate can regenerate oxidized phenolic radicals back to their active reduced forms, extending the functional antioxidant cycle. For anti-inflammatory applications, combining Vitexnegheteroin E-containing extracts with omega-3 fatty acids or boswellic acid preparations may offer complementary iNOS/COX-2 inhibitory coverage across different nodes of the arachidonic acid and nitric oxide signaling pathways.

Safety & Interactions

No formal toxicology studies, adverse event reports, or drug interaction data specific to Vitexnegheteroin E have been published, making a definitive safety assessment impossible at this time. A notable contamination concern in V. negundo callus-derived material is the presence of chlorpyrifos, an organophosphate pesticide detected at up to 42.98% in callus cultures, which could represent a significant safety risk in improperly sourced or processed material; consumers should ensure any V. negundo product is tested for pesticide residues. Pregnancy and lactation guidance cannot be provided due to the complete absence of reproductive toxicology data; consistent with precautionary principles, use during pregnancy or breastfeeding should be avoided until safety is established. Potential pharmacokinetic interactions with cytochrome P450 2C9 substrates are suggested by molecular docking data showing high binding affinity of structurally related V. negundo phenolics (e.g., cynaroside, docking score 160.22) to CYP2C9, which metabolizes drugs including warfarin, phenytoin, and NSAIDs.